Combinations of R207910 with drugs used to treat multidrug-resistant tuberculosis have the potential to shorten treatment duration (Q35127770)

6 August 2017

Combinations of R207910 with drugs used to treat multidrug-resistant tuberculosis have the potential to shorten treatment duration (English)

1 reference

6 August 2017

0 references

multiple drug resistance

1 reference

multidrug-resistant tuberculosis

inferred from title

1 reference

1 reference

Nicolas Veziris

2

0 references

author name string

Nacer Lounis

1

1 reference

6 August 2017

Aurélie Chauffour

3

1 reference

6 August 2017

Chantal Truffot-Pernot

4

1 reference

6 August 2017

Koen Andries

5

1 reference

6 August 2017

Vincent Jarlier

6

1 reference

6 August 2017

language of work or name

English

0 references

publication date

5 September 2006

1 reference

6 August 2017

5

1 reference

Antimicrobial Agents and Chemotherapy

inferred from page(s)

published in

1 reference

6 August 2017

50

1 reference

6 August 2017

3543-3547

1 reference

6 August 2017

11

1 reference

In vitro and in vivo activities of rifampin, streptomycin, amikacin, moxifloxacin, R207910, linezolid, and PA-824 against Mycobacterium ulcerans.

6 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1635167

Bactericidal activities of R207910 and other newer antimicrobial agents against Mycobacterium leprae in mice

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1635167

A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1635167

Moxifloxacin-containing regimens of reduced duration produce a stable cure in murine tuberculosis

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1635167

Fluoroquinolone-containing third-line regimen against Mycobacterium tuberculosis in vivo

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1635167

The bactericidal activity of moxifloxacin in patients with pulmonary tuberculosis

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1635167

Gatifloxacin and ethionamide as the foundation for therapy of tuberculosis

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1635167

The curious characteristics of pyrazinamide: a review

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1635167

Activities of moxifloxacin alone and in combination with other antimicrobial agents against multidrug-resistant Mycobacterium tuberculosis infection in BALB/c mice.

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1635167

Effectiveness of once-weekly rifapentine and moxifloxacin regimens against Mycobacterium tuberculosis in mice

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1635167

In vitro and in vivo activities of moxifloxacin and clinafloxacin against Mycobacterium tuberculosis.

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1635167

Which aminoglycoside or fluoroquinolone is more active against Mycobacterium tuberculosis in mice?

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1635167

Therapy of multidrug-resistant tuberculosis: lessons from studies with mice

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1635167

In vitro and in vivo activities of levofloxacin against Mycobacterium tuberculosis

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1635167

Activities of pefloxacin and ofloxacin against mycobacteria: in vitro and mouse experiments

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1635167

Experimental short-course preventive therapy of tuberculosis with rifampin and pyrazinamide

13 July 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/16954317

12 December 2020

inferred from PubMed ID database lookup

[The adverse reactions of anti-tuberculosis drugs and its management]

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/16954317

12 December 2020

inferred from PubMed ID database lookup

Identifiers

DOI

10.1128/AAC.00766-06

1 reference

6 August 2017

1 reference

6 August 2017

1 reference